Method for treating obesity
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
1 - 17 . (canceled)
18 . A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant wherein said anticonvulsant is of the formula (I):
wherein X is CH 2 or oxygen,
R 1 is hydrogen or alkyl, R 2 , R 3 , R 4 and R 5 are independently hydrogen or lower alkyl, and when X is CH 2 , R 4 and R 5 can be alkene groups joined to form a benzene ring and when X is oxygen, R 2 and R 3 and/or R 4 and R 5 together can be a methylenedioxy group of the following formula (II):
wherein
R 6 and R 7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
19 . The method of claim 18 wherein R 1 is hydrogen or a C 1 -C 4 alkyl, straight and branched chain, and R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are a C 1 -C 3 alkyl, straight or branched chain.
20 . The method of claim 18 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.
21 . The method of claim 18 , wherein said anticonvulsant is topiramate.
22 . The method of claim 18 , wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.
23 . The method of claim 18 , wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.
24 . A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant according to formula (I) in amounts such that said reduction is effected, where formula (I) is:
wherein X is CH 2 or oxygen,
R 1 is hydrogen or alkyl,
R 2 , R 3 , R 4 and R 5 are independently hydrogen or lower alkyl, and when X is CH 2 , R 4 and R 5 can be alkene groups joined to form a benzene ring and when X is oxygen, R 2 and R 3 and/or R 4 and R 5 together can be a methylenedioxy group of the following formula (II):
wherein
R 6 and R 7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
25 . A composition comprising at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine, and at least one weight-loss promoting anticonvulsant of formula (1):
wherein X is CH 2 or oxygen,
R 1 is hydrogen or alkyl,
R 2 , R 3 , R 4 and R 5 are independently hydrogen or lower alkyl, and when X is CH 2 , R 4 and R 5 can be alkene groups joined to form a benzene ring and when X is oxygen, R 2 and R 3 and/or R 4 and R 5 together can be a methylenedioxy group of the following formula (II):
wherein
R 6 and R 7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
26 . The composition of claim 25 , wherein said anticonvulsant is topiramate.
27 . The composition of claim 25 , wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.
28 . The composition of claim 25 , wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion and said anticonvulsant is topiramate.
29 . The composition of claim 25 , wherein said compound is in dosage unit form.
30 . The composition of claim 25 , wherein said composition is in the form of a tablet or capsule.